Drug developer Appili raises additional $3 mln in VC funding
Halifax anti-infective pharmaceuticals developer Appili Therapeutics Inc has raised about $3.1 million from a private placement offering. The financing, which brings total funds raised by Appili since its 2016 seed round to about $7.5 million, was backed by Canadian venture capital firm Innovacorp, as well as other new and existing investors. Appili said the offering's proceeds will help finance operations and growth. They will also advance the company's pipeline of anti-infectives and move its lead antibiotic, a taste-masked treatment for anaerobic infections, into the clinic. Founded in 2015, Appili is led by CEO Kevin Sullivan.
23 October 2017•2 mins read
